Results 31 to 40 of about 15,183 (185)

Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX [PDF]

, 2015
Summary The aim of this study was to determine the efficacy of once-weekly teriparatide as a function of baseline fracture risk. Treatment with once-weekly teriparatide was associated with a statistically significant 79 % decrease in vertebral ...
A. Odén, AC Looker, E. V. McCloskey, EV Kanis JA McCloskey, EV McCloskey, EV McCloskey, EV McCloskey, F Vescini, G Resmini, H. Johansson, HK Genant, J Reeve, J. A. Kanis, JA Kanis, JA Kanis, JA Kanis, JA Kanis, JP Devogelaer, K Kim, M. Shiraki, N. C. Harvey, R Prince, RM Neer, SP Shrader, T Fujita, T Nakamura, T. Kuroda, T. Nakamura, T. Sugimoto, Y Lu   +29 more
core   +2 more sources

Alternative treatments for oral bisphosphonate-related osteonecrosis of the jaws: a pilot study comparing fibrin rich in growth factors and teriparatide [PDF]

, 2014
Objectives: The aim of this study is to describe and compare the evolution of recurrent bisphosphonate-related osteonecrosis of the jaws (BRONJ) in patients treated with plasma rich in growth factors or teriparatide.
Gallego, Lorena, García-Consuegra, L., Gómez Alonso, Carlos, Junquera Gutiérrez, Luis Manuel, Junquera, Sonsoles, Pelaz, A.   +5 more
core   +1 more source

Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density : a randomized, double-blind, phase 2, parallel group study [PDF]

, 2018
Over 12 months, romosozumab increased bone formation and decreased bone resorption, resulting in increased bone mineral density (BMD) in postmenopausal women with low BMD (NCT00896532).
Binkley, Bone, Cosman, Cummings, Harrington, Heiss, Langdahl, Leder, Li, Li, McClung, Ominsky, Padhi, Papapoulos, Recknor, Saag, van Bezooijen, Wasnich   +17 more
core   +2 more sources

Effectiveness of Teriparatide on Fracture Healing: A Systematic Review and Meta-Analysis.

PLoS ONE, 2016
PurposeNowadays, the efficacy of teriparatide in treating osteoporosis was widely accepted, but the discussion about using teriparatide to enhance fracture healing hasn't come to an agreement.
Zhongju Shi, Hengxing Zhou, Bin Pan, Lu Lu, Jun Liu, Yi Kang, Xue Yao, Shiqing Feng   +7 more
doaj   +1 more source

Clinical efficacy of denosumab, teriparatide, and oral bisphosphonates in the prevention of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis

Journal of Orthopaedic Surgery and Research, 2023
Background Continuous use of glucocorticoids (GCs) has become the primary cause of secondary osteoporosis. Bisphosphonate drugs were given priority over denosumab and teriparatide in the 2017 American College of Rheumatology (ACR) guidelines but have a ...
Chuanjian Yuan, Yanchen Liang, Kai Zhu, Wenpeng Xie   +3 more
doaj   +1 more source

Malignant Myeloma in a Patient after Treatment for Osteoporosis with Teriparatide; a Rare Coincidence

Clinical Medicine Insights: Case Reports, 2008
A breakthrough in understanding of mechanisms of bone structure regulation has brought about the introduction of the new synthetic recombinant human parathyroid hormone 1–34 (PTH1-34; Teriparatide) in the treatment of osteoporosis.
Terje Forslund, Anna-Mari Koski, Arvo Koistinen, Anu Sikiö   +3 more
doaj   +1 more source

Does Discontinuing Teriparatide Treatment and Replacing It with Bisphosphonate Maintain the Volume of the Bone Fusion Mass after Lumbar Posterolateral Fusion in Women with Postmenopausal Osteoporosis? [PDF]

Asian Spine Journal, 2017
Study DesignRetrospective case series.PurposeThe purpose of this study was to determine whether discontinuing teriparatide treatment and replacing it with bisphosphonate treatment maintains the volume of the fusion mass after posterolateral fusion (PLF ...
Seiji Ohtori, Sumihisa Orita, Kazuyo Yamauchi, Yawara Eguchi, Yasuchika Aoki, Junichi Nakamura, Miyako Suzuki, Gou Kubota, Kazuhide Inage, Yasuhiro Shiga, Koki Abe, Kazuki Fujimoto, Hirohito Kanamoto, Masahiro Inoue, Hideyuki Kinoshita, Takeo Furuya, Masao Koda   +16 more
doaj   +1 more source

Surgical outcome of atypical subtrochanteric and femoral fracture related to bisphosphonates use in osteoporotic patients with or without teriparatide treatment

BMC Musculoskeletal Disorders, 2017
Background Atypical subtrochanteric fracture and femoral fracture have been considered to be rare complications related to long-term bisphosphonates use. A reduced bone turnover rate may lead to delayed bone healing.
Wen-Ling Yeh, Chun-Yi Su, Chia-Wei Chang, Chien-Hao Chen, Tsai-Sheng Fu, Lih-Huei Chen, Tung-Yi Lin   +6 more
doaj   +1 more source

Assessing osteoporosis in the young adult [PDF]

, 2015
Osteoporosis in the young adult is a relatively rare phenomenon, and its diagnosis needs careful assessment of the affected person. The emphasis in the assessment of bone health is gradually shifting from a simple quantitative assessment of bone mineral ...
Ahmed, Syed Faisal, Choong, Wong Sze, Gallacher, Stephen   +2 more
core   +1 more source

Effects of denosumab versus teriparatide in glucocorticoid-induced osteoporosis patients with prior bisphosphonate treatment

Bone Reports, 2020
Introduction: Osteoporosis is one of the serious adverse effects associated with glucocorticoid therapy. Although bisphosphonates have been used for glucocorticoid-induced osteoporosis (GIO), some patients have shown an inadequate response. In such cases,
Yasuaki Hirooka, Yuji Nozaki, Asuka Inoue, Jinhai Li, Toshihiko Shiga, Kazuya Kishimoto, Masafumi Sugiyama, Koji Kinoshita, Masanori Funauchi, Itaru Matsumura   +9 more
doaj   +1 more source